14-GI-94-OI (OX4219S) Rollover fosbretabulin study in NET patients with elevated biomarkers

Grants and Contracts Details

StatusFinished
Effective start/end date4/20/159/30/17

Funding

  • Pharm Olam International: $152,264.00